Sign In
Buy SESN
$0.629
+0 (+0%)
At Close: Jun 06, 2023
Sesen Bio Stockholders Approve Merger with Carisma Therapeutics
11:32am, Thursday, 02'nd Mar 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that its stockholders have voted to approve all proposals, including the pendi
Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results
08:00am, Tuesday, 28'th Feb 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN) today reported operating results for the fourth quarter and full year ended December 31, 2022, and provided a business update. Business Upda
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that leading independent proxy advisory firm Glass, Lewis & Co. (“Glass Lewi
Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting
04:42pm, Thursday, 16'th Feb 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that Institutional Shareholder Services (“ISS”) recommends that stockholde
Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger
08:00am, Thursday, 16'th Feb 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) today announced that members of its management team will host a fireside chat with members of the Carisma Therapeutics Inc. (“Carism
BML, One of Sesen Bio's Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics
08:00am, Wednesday, 15'th Feb 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that BML Investment Partners, L.P. (“BML”), one of Sesen Bio's top stockho
Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger
08:00am, Tuesday, 14'th Feb 2023
CAMBRIDGE, Mass. & PHILADELPHIA--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) and Carisma Therapeutics Inc. (Carisma), a privately-held, clinical stage biopharmaceutical company focused on discover
Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger
04:30pm, Thursday, 02'nd Feb 2023
CAMBRIDGE, Mass.--( BUSINESS WIRE )--Sesen Bio, Inc. (NASDAQ: SESN) today filed an investor presentation highlighting its value maximizing merger with Carisma Therapeutics Inc. (“Carisma”). The pr
Sesen Bio Receives NASDAQ Delisting Notice
08:00am, Monday, 30'th Jan 2023
CAMBRIDGE, Mass.--( BUSINESS WIRE )--Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”) today announced that it has received notice from the Listing Qualifications Department of The
Sesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of Stockholders
08:00am, Thursday, 26'th Jan 2023
CAMBRIDGE, Mass.--( BUSINESS WIRE )--Sesen Bio, Inc. (Nasdaq: SESN) today issued the following statement reiterating the Company's confidence in, and commitment to, the pending merger with Carisma The
Investor Group Issues Letter to the Boards of Sesen Bio and Carisma Rejecting Their Apparent Attempt to Purchase Merger Support
10:36am, Wednesday, 25'th Jan 2023
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok (together with their affiliates, the “Investor Group” or “we”), who own approximately 8.4% of the outstanding common stock of Sese
Investor Group Issues Letter to the Boards of Sesen Bio and Carisma Rejecting Their Apparent Attempt to Purchase Merger Support
08:00am, Wednesday, 25'th Jan 2023
HOUSTON--( BUSINESS WIRE )--Bradley L. Radoff and Michael Torok (together with their affiliates, the “Investor Group” or “we”), who own approximately 8.4% of the outstanding common stock of Se
SESEN BIO, INC. (SESN) Upgraded to Buy: What Does It Mean for the Stock?
01:33pm, Wednesday, 30'th Nov 2022
SESEN BIO, INC. (SESN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Bradley Louis Radoff Discloses Activist Position in SESN / Sesen Bio
03:42am, Tuesday, 22'nd Nov 2022
Fintel reports that Radoff Bradley Louis has filed a 13D form with the SEC disclosing ownership of 6,000,000 shares of Sesen Bio Inc (SESN).
7 Cheap Penny Stocks To Buy For Under $1 Right Now
02:00pm, Monday, 07'th Nov 2022
Penny stocks under $1: Are they worth the risk to buy right now? The post 7 Cheap Penny Stocks To Buy For Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS
